Trials / Terminated
TerminatedNCT00193102
Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The lack of non-overlapping toxicities between the two drugs, the ease of all oral drug administration, and the possibility for antitumor synergy make exploration of this combination regimen attractive in women with previously treated metastatic breast cancer. This phase II trial will be performed in collaboration with the Minnie Pearl Cancer Research Network, a multicenter, community-based clinical trials group.
Detailed description
Upon determination of eligibility, patients will be receive: Thalidomide + Capecitebine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thalidomide | Thalidomide |
| DRUG | Capecitabine | Capecitabine |
Timeline
- Start date
- 2001-04-01
- Primary completion
- 2005-02-01
- Completion
- 2010-06-01
- First posted
- 2005-09-19
- Last updated
- 2011-05-03
Source: ClinicalTrials.gov record NCT00193102. Inclusion in this directory is not an endorsement.